Motesanib Shown Active Against Progressive, Differentiated Thyroid Cancer

Motesanib, an angiogenesis inhibitor, induced partial responses in a phase II study of 93 patients with progressive, locally advanced/metastatic, differentiated thyroid cancer, researchers reported in the July 3 issue of the New England Journal of Medicine.




More Stories in Americal College of Emergency Physicians

    Other Feedables